3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
19
Neoplasms
11
Polycystic Ovary Syndrome
9
Neoplasm Metastasis
4
Multiple Myeloma
4
Melanoma
4
Vomiting
3
Prostatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Solid Tumors
2
Skin Neoplasms
2
Sarcoma
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Peripheral Nervous System Diseases
2
Ovarian Neoplasms
2
Obesity
2
Nausea
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, B-Cell
2
Leukemia
2
Insulin Resistance
2
Inflammation
2
Diabetes Mellitus
2
Colorectal Neoplasms
2
Cognitive Dysfunction
2
Interventions
Doxorubicin
6
Ifosfamide
5
Radiotherapy
4
pazopanib
3
cediranib
3
atezolizumab
3
Sunitinib
3
selinexor
2
perifosine
2
pembrolizumab
2
Trabectedin
2
Specimen Handling
2
Loperamide
2
Gemcitabine
2
Filgrastim
2
Dacarbazine
2
Cisplatin
2
Biopsy
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
spartalizumab
1
sargramostim
1
romidepsin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
ixazomib
1
indolepropanol phosphate
1
futibatinib
1
fludarabine
1
cabozantinib
1
brostallicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma, Alveolar Soft Part
×
Tablets
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled